Nimodipine improves regional cerebral blood flow and suppresses inflammatory factors in the hippocampus of rats with vascular dementia

Journal of International Medical Research

Volumn 40, Issue 3, 2012, Pages 1036-1045

  Zhang, X L ^a   Zheng, S L ^a   Dong, F R ^a   Wang, Zhi Ming ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Calcium channel blocker; Cerebral blood flow; Cognitive function; Cytokines; Hippocampus; Morris water maze test; Nimodipine; Vascular dementia

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; NIMODIPINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HIPPOCAMPUS; LEARNING; MALE; MAZE TEST; MEMORY; MULTIINFARCT DEMENTIA; NERVE CELL; NONHUMAN; PERFUSION WEIGHTED IMAGING; PROTEIN EXPRESSION; RAT; TREATMENT RESPONSE;

EID: 84863103452     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000322     Document Type: Article

References (38)

1. Lüders S, Stöve S, Schrader J: Prevention of vascular dementia. Evidence and practice. Internist (Berl) 2012; 53: 223-231 [in German, English abstract].
2. Yagami T: Cerebral arachidonate cascade in dementia: Alzheimer's disease and vascular dementia. Curr Neuropharmacol 2006; 4: 87-100.
3. Zhang B, Wu HQ, Zhang HX: Neurobiochemical mechanisms of vascular dementia. Foreign Medical Sciences (Cerebrovascular Diseases) 2005; 13: 672-675 [in Chinese].
4. 125I]endothelin in rat and human brain. Neurosci Lett 1989; 97: 276-279.
5. Min D, Mao X, Wu K, et al: Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. Neurosci Lett 2012; 510: 29-33.
6. Zekry D, Duyckaerts C, Belmin J, et al: The vascular lesions in vascular and mixed dementia: the weight of functional neuroanatomy. Neurobiol Aging 2003; 24: 213-219.
7. Angelopoulos P, Agouridaki H, Vaiopoulos H, et al: Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci 2008; 118: 1659-1672.
8. Rosenberg GA: Inflammation and white matter damage in vascular cognitive impairment. Stroke 2009; 40(3 suppl): S20-S23.
9. Trollor JN, Smith E, Baune BT, et al: Systemic inflammation is associated with MCI and its subtypes: the Sydney Memory and Aging Study. Dement Geriatr Cogn Disord 2010; 30: 569-578.
10. Batti L, O'Connor JJ: Tumor necrosis factor-1 impairs the recovery of synaptic transmission from hypoxia in rat hippocampal slices. J Neuroimmunol 2010; 218: 21-27.
11. Zuliani G, Ranzini M, Guerra G, et al: Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007; 41: 686-693.
12. Pennisi G, Ferri R, Cantone M, et al: A review of transcranial magnetic stimulation in vascular dementia. Dement Geriatr Cogn Disord 2011; 31: 71-80.
13. Cohen RA: Hypertension and cerebral blood flow: implications for the development of vascular cognitive impairment in the elderly. Stroke 2007; 38: 1715-1717.
14. Iadecola C: The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120: 287-296.
15. Bennett S, Grant MM, Aldred S: Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. J Alzheimers Dis 2009; 17: 245-257.
16. Kirvell SL, Elliott MS, Kalaria RN, et al: Vesicular glutamate transporter and cognition in stroke: a case-control autopsy study. Neurology 2010; 75: 1803-1809.
17. Zhang HZ, Zhang LX, She YF, et al: Effect of electroacupuncture on apoptosis of hippocampus tissue in mice with vascular dementia. Zhen Ci Yan Jiu 2008; 33: 377-381 [in Chinese, English abstract].
18. Baskys A, Hou AC: Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging 2007; 2: 327-335.
19. Lockman JA, Geldenhuys WJ, Bohn KA, et al: Differential effect of nimodipine in attenuating iron-induced toxicity in brain-and blood-brain barrier-associated cell types. Neurochem Res 2012; 37: 134-142.
20. Bekker A, Haile M, Li YS, et al: Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice. Anesth Analg 2009; 109: 1943-1948.
21. Lindsay RW, Heaton JT, Edwards C, et al: Nimodipine and acceleration of functional recovery of the facial nerve after crush injury. Arch Facial Plast Surg 2010; 12: 49-52.
22. Aslan A, Gurelik M, Cemek M, et al: Nimodipine can improve cerebral metabolism and outcome in patients with severe head trauma. Pharmacol Res 2009; 59: 120-124.
23. Pantoni L, del Ser T, Soglian AG, et al: Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebocontrolled trial. Stroke 2005; 36: 619-624.
24. O'Brien JT, Burns A, BAP Dementia Consensus Group: Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 997-1019.
25. Doody RS, Stevens JC, Beck C, et al: Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-1166.
26. Choi SK, Lee GJ, Choi S, et al: Neuroprotective effects by nimodipine treatment in the experimental global ischemic rat model: real time estimation of glutamate. J Korean Neurosurg Soc 2011; 49: 1-7.
27. Yanpallewar SU, Hota D, Rai S, et al: Nimodipine attenuates biochemical, behavioral and histopathological alterations induced by acute transient and long-term bilateral common carotid occlusion in rats. Pharmacol Res 2004; 49: 143-150.
28. Ma B, Zhang J: Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage. Brain Res 2006; 1078: 182-188.
29. Animal Care and Use Committee: Guidelines for the capture, handling, and care of mammals as approved by the American Society of Mammalogists. J Mammal 1988; 79: 1416-1431.
30. Longa EZ, Weinstein PR, Carlson S, et al: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
31. Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
32. Haile M, Limson F, Gingrich K, et al: Nimodipine prevents transient cognitive dysfunction after moderate hypoxia in adult mice. J Neurosurg Anesthesiol 2009; 21: 140-144.
33. Li Y, Hu X, Liu Y, et al: Nimodipine protects dopaminergic neurons against inflammationmediated degeneration through inhibition of microglial activation. Neuropharmacology 2009; 56: 580-589.
34. Terrando N, Eriksson LI, Kyu Ryu J, et al: Resolving postoperative neuroinflammation and cognitive decline. Ann Neurol 2011; 70: 986-995.
35. Nishio K, Ihara M, Yamasaki N, et al: A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 2010; 41: 1278-1284.
36. Erdem AF, Cesur M, Alici HA, et al: Effects of sevoflurane and desflurane in CA1 after incomplete cerebral ischemia in rats. Saudi Med J 2005; 26: 1424-1428.
37. Seguin JA, Brennan J, Mangano E, et al: Proinflammatory cytokines differentially influence adult hippocampal cell proliferation depending upon the route and chronicity of administration. Neuropsychiatr Dis Treat 2009; 5: 5-14.
38. Yang SY, Wang ZG: Therapeutic effect of nimodipine on experimental brain injury. Chin J Traumatol 2003; 6: 326-331.